Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
06 Agosto 2024 - 5:00PM
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the
“Company”), a clinical-stage biopharmaceutical company developing a
novel therapeutic that targets toxic soluble amyloid beta oligomers
for the treatment of Alzheimer’s disease, today announced that the
Company will report second quarter 2024 financial results on
Tuesday, August 13, 2024. The Company will host a conference call
and live audio webcast at 8:00 a.m. ET to provide a business and
financial update.
To participate in the live conference call,
please register using this link. After registration, you will be
informed of the dial-in numbers including PIN. Please register at
least one day in advance.
The webcast audio will be available via
this link.
An archived version of the webcast will be available for at
least 30 days in the Investors section of the Company's website
at www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical
company developing a novel therapeutic that targets toxic soluble
amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s
disease (AD). Acumen’s scientific founders pioneered research on
AβOs, which a growing body of evidence indicates are early and
persistent triggers of Alzheimer’s disease pathology. Acumen is
currently focused on advancing its investigational product
candidate, sabirnetug (ACU193), a humanized monoclonal antibody
that selectively targets toxic soluble AβOs, in its ongoing Phase 2
clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic
Alzheimer’s disease patients, following positive results in its
Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton,
Mass. For more information,
visit www.acumenpharm.com.
Investors: Alex Braunabraun@acumenpharm.com
Media: AcumenPR@westwicke.com
Acumen Pharmaceuticals (NASDAQ:ABOS)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Acumen Pharmaceuticals (NASDAQ:ABOS)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024